Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Immunocore is a leading clinical-stage T Cell Receptor (TCR) biotechnology company delivering first-in-class biological therapies, focused on oncology, infectious and autoimmune diseases.

Immunocore is building a new class of biologic drugs with its proprietary novel TCR-based technology for immunotherapies. It has developed technology focused on small protein molecules called Immune mobilising T cell receptors against Cancer (ImmTAC®) which enables the immune system to recognise and kill cancerous or bacterially/virally infected cells. ImmTAC® molecules are soluble TCRs that naturally recognise diseased cells with ultra-high affinity and enable circulating T cells to selectively identify, link to and kill diseased cells, via a highly potent immune response.

Immunocore has a pipeline of proprietary and partnered development programmes and while its primary therapeutic focus is oncology, it also carries programmes in infectious and autoimmune diseases. Immunocore’s lead programme is in a pivotal clinical study as a treatment for patients with metastatic uveal melanoma, currently an unmet need.

In addition to a well-established pipeline of wholly owned programmes, Immunocore’s transformational science and strong IP position has led to multi-target discovery partnerships, including milestones and royalties, with Genentech, GlaxoSmithKline and AstraZeneca to develop new cancer therapies using the ImmTAC® technology platform.

Outside of oncology, the Bill and Melinda Gates Foundation is supporting the expansion of Immunocore’s technology platform to develop ImmTAV and ImmTAB molecules for the treatment of infectious diseases.

Immunocore Pipeline

Candidate

Indication

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal

Tebentafusp/IMCgp100

Uveal melanoma

Tebentafusp/IMCgp100 checkpoint combination

Cutaneous melanoma

GSK1 (IMCnyeso)

Synovial / bladder / melanoma /
non-small cell lung cancer

IMC-C103C (MAGE-A4)

Non-small cell lung cancer /
oesophageal / others

IMC-F106C (PRAME)

Non-small cell lung cancer /
breast / ovarian / others

IMC-I109V

Chronic HBV

IMC-J11OC

Liver / gastric / head & neck / bladder / others

Candidate: Tebentafusp/IMCgp100

Indication: Uveal melanoma

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: Tebentafusp/IMCgp100 checkpoint combination

Indication: Cutaneous melanoma

Owner: Immunocore / MedImmune

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: GSK1 (IMCnyeso)

Indication: Synovial / bladder / melanoma /
non-small cell lung cancer

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-C103C (MAGE-A4)

Indication: Non-small cell lung cancer /
oesophageal / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-F106C (PRAME)

Indication: Non-small cell lung cancer /
breast / ovarian / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-I109V

Indication: Chronic HBV

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-J11OC

Indication: Liver / gastric / head & neck / bladder / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal